Signal Genetics Inc Stock Nasdaq
Equities
US8266401046
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Financials (USD)
Sales 2024 * | 370K | Sales 2025 * | 330K | Capitalization | 766M |
---|---|---|---|---|---|
Net income 2024 * | -230M | Net income 2025 * | -266M | EV / Sales 2024 * | 820 x |
Net cash position 2024 * | 462M | Net cash position 2025 * | 625M | EV / Sales 2025 * | 426 x |
P/E ratio 2024 * |
-3.24
x | P/E ratio 2025 * |
-3.06
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.26% |
Latest transcript on Signal Genetics Inc
Managers | Title | Age | Since |
---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 23-10-29 |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 23-04-30 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 18-01-02 |
Tomas Kiselak
CHM | Chairman | 37 | 20-10-27 |
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 23-10-29 |
1st Jan change | Capi. | |
---|---|---|
+48.64% | 54.63B | |
-6.44% | 39.92B | |
+37.07% | 38.82B | |
+14.28% | 26.86B | |
-11.17% | 26.22B | |
-21.40% | 18.78B | |
+25.64% | 12.21B | |
+0.96% | 12.16B | |
+27.04% | 11.94B |